Patients News | pharmaphorum

News

First-in-class hay fever immunotherapy backed for NHS use

A once-daily tablet that can help people suffering from hay fever caused by tree pollen, Alk-Abelló's Itulazax, has been recommended for NHS use.

News

A woman holds her hands up in a signal of 'No'

Sarepta resists as FDA seeks pause on Elevidys use

Sarepta has defied an FDA request to halt all use of its gene therapy for Duchenne muscular dystrophy, creating an intriguing regulatory impasse.

News

Third death reported with a Sarepta gene therapy

A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles being faced by the company.

News

BMS, Pfizer take DTC route for blood thinner Eliquis

BMS, Pfizer launch direct-to-patient sales for anticoagulant Eliquis, as a report cites conflict-of-interest concerns about the emerging DTC channel.

News

UK plans to invest 'billions' in Essex biosecurity centre

The UK government has revealed a plan to open a multibillion-pound biosecurity facility to protect the country from emerging public health threats.

News

Daniel Nadler, co-founder and chief executive of OpenEvidence

Medical chatbot firm OpenEvidence raises $210m

OpenEvidence has raised $210m to expand the capabilities of its physician decision-making tool and launch a new service offering 'PhD-level' research.

First-in-class hay fever immunotherapy backed for NHS use

Sarepta resists as FDA seeks pause on Elevidys use

Third death reported with a Sarepta gene therapy

BMS, Pfizer take DTC route for blood thinner Eliquis

UK plans to invest 'billions' in Essex biosecurity centre

Medical chatbot firm OpenEvidence raises $210m

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

News

Editor's Picks